100763
论文已发表
提 交 论 文
注册即可获取Ebpay生命的最新动态
注 册
IF 收录期刊
- 3.3 Breast Cancer (Dove Med Press)
- 3.4 Clin Epidemiol
- 2.5 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.5 Clin Interv Aging
- 4.7 Drug Des Dev Ther
- 2.7 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.5 Int J Women's Health
- 2.5 Neuropsych Dis Treat
- 2.7 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.3 Ther Clin Risk Manag
- 2.5 J Pain Res
- 2.8 Diabet Metab Synd Ob
- 2.8 Psychol Res Behav Ma
- 3.0 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.7 Risk Manag Healthc Policy
- 4.2 J Inflamm Res
- 2.1 Int J Gen Med
- 4.2 J Hepatocell Carcinoma
- 3.7 J Asthma Allergy
- 1.9 Clin Cosmet Investig Dermatol
- 2.7 J Multidiscip Healthc
阿帕替尼成功治疗转移性结直肠癌：病例报道两例及文献回顾
Authors Bi MH, Yang JR, Wang YP, Zhang HR, Gao ZY, Zhou HR, Shi MH
Received 6 August 2017
Accepted for publication 28 December 2017
Published 19 February 2018 Volume 2018:11 Pages 883—890
DOI http://doi.org/10.2147/OTT.S148412
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Akshita Wason
Peer reviewer comments 2
Editor who approved publication: Dr Ingrid Espinoza
摘要：阿帕替尼是一种能够抑制血管内皮细胞生长因子受体-2 的新型单克隆抗体，在 2014 年 10 月在中国被批准用于转移性胃腺癌的治疗。本文首次报道了阿帕替尼作为三线用药用于治疗进展期结直肠癌的两例成功个案。文中我们报道了两例转移性结直肠癌的中国患者，在接受阿帕替尼 850mg/天作为三线治疗后，均取得了很好的疗效。患者I服药后取得了 4 个月的无进展生存期，总生存期达 11 个月，患者 II 服药后的无进展生存期超过了 10 个月。两例患者在服用阿帕替尼期间均出现了手足综合征，其中一例还出现了轻度的肝功能损害及血压升高，蛋白尿。但这些副反应经对症治疗及减量服药或短期停药后均得到了很好的控制与缓解。
Keywords: vascular
endothelial growth factor, large intestine cancer, apatinib, targeted therapy,
antiangiogenesis, tyrosine kinase inhibitor
摘要视频链接：Treatment of metastatic CRC
with apatinib
